Steven Cohen's SNDX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.99 M shares of Syndax Pharmaceuticals, Inc. (SNDX) worth $46.38 M, representing 0.06% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in SNDX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 2.13 M shares. Largest reduction occurred in Q1 2026, reducing 2.9 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Syndax Pharmaceuticals (SNDX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Syndax Pharmaceuticals (SNDX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -2.9 M | Reduce 59.33% | 1.99 M | $23.36 |
| Q4 2025 | +627,006 | Add 14.74% | 4.88 M | $21.01 |
| Q3 2025 | +2.13 M | Add 100.01% | 4.26 M | $15.39 |
| Q2 2025 | -1.88 M | Reduce 46.93% | 2.13 M | $9.37 |
| Q1 2025 | +2.09 M | Add 109.25% | 4.01 M | $12.29 |
| Q4 2024 | -862,531 | Reduce 31.05% | 1.92 M | $13.22 |
| Q3 2024 | -4,586 | Reduce 0.16% | 2.78 M | $19.25 |
| Q2 2024 | +716,168 | Add 34.65% | 2.78 M | $20.53 |
| Q1 2024 | -767,814 | Reduce 27.09% | 2.07 M | $23.80 |
| Q4 2023 | +740,298 | Add 35.35% | 2.83 M | $21.61 |
| Q3 2023 | +859,401 | Add 69.60% | 2.09 M | $14.52 |
| Q2 2023 | +710,400 | Add 135.47% | 1.23 M | $20.93 |
| Q1 2023 | -399,000 | Reduce 43.21% | 524,400 | $21.12 |
| Q4 2022 | +923,400 | New Buy | 923,400 | $25.45 |
| Q2 2022 | -360,000 | Sold Out | 0 | $0.00 |
| Q1 2022 | +6,900 | Add 1.95% | 360,000 | $17.38 |
| Q4 2021 | -107,800 | Reduce 23.39% | 353,100 | $21.89 |
| Q3 2021 | +148,500 | Add 47.54% | 460,900 | $19.11 |
| Q2 2021 | -634,400 | Reduce 67.00% | 312,400 | $17.17 |
| Q1 2021 | -197,100 | Reduce 17.23% | 946,800 | $22.36 |
| Q4 2020 | +977,863 | Add 588.94% | 1.14 M | $22.24 |
| Q3 2020 | +166,037 | New Buy | 166,037 | $14.76 |
| Q4 2018 | -170,000 | Sold Out | 0 | $0.00 |
| Q3 2018 | +170,000 | New Buy | 170,000 | $8.08 |
| Q2 2018 | -300,000 | Sold Out | 0 | $0.00 |
| Q1 2018 | +300,000 | New Buy | 300,000 | $14.23 |
| Q2 2017 | -99,000 | Sold Out | 0 | $0.00 |
| Q1 2017 | +99,000 | New Buy | 99,000 | $13.72 |
Steven Cohen's Syndax Pharmaceuticals Investment FAQs
Steven Cohen first purchased Syndax Pharmaceuticals, Inc. (SNDX) in Q1 2017, acquiring 99,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Syndax Pharmaceuticals, Inc. (SNDX) for 28 quarters since Q1 2017.
Steven Cohen's largest addition to Syndax Pharmaceuticals, Inc. (SNDX) was in Q3 2025, adding 4,255,047 shares worth $65.46 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,985,547 shares of Syndax Pharmaceuticals, Inc. (SNDX), valued at approximately $46.38 M.
As of the Q1 2026 filing, Syndax Pharmaceuticals, Inc. (SNDX) represents approximately 0.06% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Syndax Pharmaceuticals, Inc. (SNDX) was 4,882,053 shares, as reported at the end of Q4 2025.